NASDAQ: KROSKeros Therapeutics Inc Stock
$14.07+0.54 (+3.99%)
Updated Apr 17, 2025
KROS Price
$14.07
Fair Value Price
$13.89
Market Cap
$570.71M
52 Week Low
$9.12
52 Week High
$72.37
P/E
-2.81x
P/B
1x
P/S
166.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.55M
Earnings
-$187.35M
Gross Margin
100%
Operating Margin
-5,269.1%
Profit Margin
-5,277.5%
Debt to Equity
0.08
Operating Cash Flow
-$161M
Beta
1.14
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
KROS Overview
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KROS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KROS
Ranked#237 of 463
Ranked#237 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important KROS news, forecast changes, insider trades & much more!
KROS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KROS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KROS ($14.07) is overvalued by 1.27% relative to our estimate of its Fair Value price of $13.89 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KROS ($14.07) is not significantly undervalued (1.27%) relative to our estimate of its Fair Value price of $13.89 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KROS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KROS due diligence checks available for Premium users.
Valuation
KROS fair value
Fair Value of KROS stock based on Discounted Cash Flow (DCF)
Price
$14.07
Fair Value
$13.89
Overvalued by
1.27%
KROS ($14.07) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KROS ($14.07) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KROS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KROS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.81x
Industry
-177.72x
Market
27.98x
KROS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1x
Industry
4.05x
KROS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KROS's financial health
Profit margin
Revenue
$3.0M
Net Income
-$46.0M
Profit Margin
-1,513%
KROS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KROS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$615.9M
Liabilities
$44.3M
Debt to equity
0.08
KROS's short-term assets ($588.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KROS's short-term assets ($588.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KROS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KROS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$46.0M
Investing
-$289.0k
Financing
$75.5M
KROS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KROS vs Biotech Stocks
Keros Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.